AIRR - ANZCA Institutional Research Repository
Skip navigation
Please use this identifier to cite or link to this item: http://hdl.handle.net/11055/908
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFinch PMen_US
dc.contributor.authorPrice LMen_US
dc.contributor.authorPullan PTen_US
dc.contributor.authorDrummond PDen_US
dc.date.accessioned2019-11-15T00:40:05Z-
dc.date.available2019-11-15T00:40:05Z-
dc.date.issued2015-04-
dc.identifier.citation15(4):308-13en_US
dc.identifier.urihttp://hdl.handle.net/11055/908-
dc.description.abstractBACKGROUND: Opioid induced depression of sex hormones is a common finding in chronic pain patients receiving long-term opioids by oral, parenteral and even intrathecal routes of administration. The hypothalamic suppression by opioids leads to a hypogonadal state with low testosterone levels in males and subsequent low bone mineral density (BMD). METHODS: We have studied the effects of intrathecally administered opioids on BMD in a group of male chronic pain patients. In addition, we have studied the effects of supplementary testosterone on bone metabolism to see if the adverse effects of intrathecal opioids can be reversed. RESULTS: Eleven of the 27 patients were on supplementary testosterone having previously been diagnosed as hypogonadal with low serum testosterone. Duration of testosterone supplementation was greater than 2 years in all 11 patients. Both serum total and free testosterone levels were higher in patients on supplementary testosterone than in patients who did not receive this treatment. Of the 16 patients not on testosterone supplement, 14 (87%) had low serum testosterone levels (<10 nmol/L) and 11 (69%) had low or osteoporotic T scores. Within this group, low free testosterone was associated with low BMD scores, and this persisted after correcting for age. Eight of the patients on testosterone supplement had normal BMDT scores and three (27%) had low or osteoporotic T scores. T and age-corrected BMDZ scores were significantly greater in the 11 patients on testosterone supplements than BMD scores in the other 16 patients. CONCLUSION: Testosterone supplementation was found to largely correct the effects of intrathecal opioids on testosterone levels and BMD.en_US
dc.subjectageden_US
dc.subjectanalgesics, opioid/administration & dosageen_US
dc.subjectanalgesics, opioid/adverse effectsen_US
dc.subjectbone density/drug effectsen_US
dc.subjectchronic pain/drug therapyen_US
dc.subjecthypogonadism/drug therapyen_US
dc.subjectinjections, spinalen_US
dc.subjectanalgesics, opioiden_US
dc.subjecttestosterone/therapeutic useen_US
dc.titleEffects of testosterone treatment on bone mineral density in hypogonadal men receiving intrathecal opioidsen_US
dc.typeJournal Articleen_US
dc.type.contentTexten_US
dc.identifier.journaltitlePain practice : the official journal of World Institute of Painen_US
dc.identifier.doi10.1111/papr.12190en_US
dc.type.studyortrialStudyen_US
dc.contributor.anzcaFinch, PMen_US
Appears in Collections:Scholarly and Clinical

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.